Vertex制药公司(VRTX)盘后股价大涨10.10%,引发了市场的广泛关注。
数据显示,Vertex公司的Journavx非阿片类止痛药获得美国食品药品管理局(FDA)批准,用于治疗成人中度至重度急性疼痛。这是数十年来首个上市的新型非阿片类止痛药,被认为比阿片类止痛药更加安全,避免了上瘾的风险。
另外,英国国家医疗服务体系将为镰状细胞病患者提供Vertex与CRISPR公司合作开发的基因治疗项目,每个疗程费用约210万美元。该项目使用CRISPR基因编辑技术,有望从根本上治愈疾病。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.